No announcement yet.

Teva's Copaxone replacement falls short

  • Filter
  • Time
  • Show
Clear All
new posts

  • Teva's Copaxone replacement falls short

    Oral drugs continue to be tricky. Disappointing, but it does reinforce the effectiveness of our current FDA-approved treatments. - Dave


    Teva Pharmaceutical Industries Ltd. and Active Biotech announced in a press release that the phase III BRAVO study, in which the experimental oral drug laquinimod was tested against inactive placebo in a study involving over 1300 people with relapsing-remitting MS, did not reach its primary goal of reducing the average number of relapses in a year. However, when the investigators adjusted the data to correct for differences in magnetic resonance imaging characteristics at the start of the study, a significant reduction in average annual relapse rate was observed in the group receiving the laquinimod. Further analysis is ongoing, and the results are being submitted for presentation at a scientific meeting later this year. The companies state that they plan to submit applications to regulatory authorities for the treatment of MS in the United States and European Union.

    Full article:
    Dave Bexfield